explore -WSS

explore

author：fashion 2025-09-28 18:47:31 - browse：3198

illustration of a colorful DNA strand, partly broken into pieces. -- health coverage from STAT — Adobe

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells. If the patient ever stops taking medicines, those cells start pumping out HIV particles and the infection roars back.

Researchers hoped they could send CRISPR to those cells and, by cutting the HIV DNA lurking there at two spots, slice out the virus. In the Phase 1 trial, investigators administered the treatment to five patients. They then took three of them off conventional antiviral treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Letters to First Opinion on caregivers, digital health, and more

hotspot

WSS

Letters to First Opinion on caregivers, digital health, and more

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Wegovy trial has doctors encouraged over new possibilities

Wegovy trial has doctors encouraged over new possibilities

Innovation in antibiotics is ailing. 'Brain drain' may kill it

American woman, child freed after being kidnapped in Haiti last month

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Anavex keeps shifting the goalposts in its clinical trials

Anesthesiologist group: stop taking Ozempic before surgery

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Medical leaders decry Supreme Court decision on affirmative action

How to increase colonoscopy rates? Looks like an AI can help

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why failed clinical trials don’t always spell doom for a new drug

Dobbs anniversary: the lost opportunity of abortion as health care

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

focus

NIH documents show early flaws of $1.6 billion long Covid program

ASCO: Palliative care found as helpful given virtually as in person

Ultragenyx gene therapy for rare liver ailment succeeds in late

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Why failed clinical trials don’t always spell doom for a new drug

Methadone doses haven’t kept up in the age of fentanyl

hotspot

explore

hotspot

focus